Vancouver, British Columbia–(Newsfile Corp. – October 27, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its operations and progress on its strategic initiatives. Observational Study Update Entheon is pleased to announce…
